Aclaris Therapeutics, INC. (ACRS) — 10-Q Filings

10-Q Filings (6)

• Aclaris' Net Loss Widens 27% Amid Soaring R&D Costs — Nov 6, 2025 Risk: high
  Aclaris Therapeutics, Inc. (ACRS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $45.1 million, up from $35.
• Aclaris' Q2 Loss Widens to $24.7M Amid R&D Pipeline Focus — Aug 7, 2025 Risk: high
  Aclaris Therapeutics, Inc. reported a net loss of $24.7 million for the quarter ended June 30, 2025, a significant increase from the net loss of $19.9 million i
• Aclaris Therapeutics Q1 2025 10-Q Filing — May 8, 2025 Risk: low
  Aclaris Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware and headquartered in Wayne, PA
• Aclaris Therapeutics Reports Net Liability — Nov 6, 2024 Risk: high
  Aclaris Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $70.9 million and total liabilities of
• Aclaris Therapeutics Reports Q2 2024 Financials — Aug 7, 2024 Risk: medium
  Aclaris Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $70.9 million and total liabilities of $71.3
• Aclaris Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk:
  Aclaris Therapeutics, Inc. (ACRS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Aclaris Therapeutics reported total assets of $70.9 million as of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX